3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
2
Multiple Myeloma
2
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Blast Crisis
1
Anemia
1
Interventions
pembrolizumab
126
Carboplatin
108
Pemetrexed
76
Paclitaxel
76
Cisplatin
73
Nivolumab
56
Docetaxel
53
Erlotinib Hydrochloride
50
Gemcitabine
49
Radiotherapy
48
Bevacizumab
32
osimertinib
31
Cetuximab
29
atezolizumab
25
Cyclophosphamide
25
durvalumab
24
130-nm albumin-bound paclitaxel
22
Oxaliplatin
19
Fluorouracil
18
Taxes
17
Radiosurgery
17
fludarabine
16
Magnetic Resonance Spectroscopy
16
Gefitinib
16
Ipilimumab
15
Vinorelbine
14
Leucovorin
14
Albumin-Bound Paclitaxel
14
Vorinostat
13
Radiation
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Non-Small-Cell Lung
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05650879
2025-07-15
HER2
Enliven Therapeutics
Phase 1
Active not recruiting
198 enrolled